Home Blog Page 3456

Zepp Health Corporation Files 2024 Annual Report on Form 20-F

MILPITAS, Calif., April 26, 2025 /PRNewswire/ — Zepp Health Corporation (“Zepp Health” or the “Company”) (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it has filed its annual report on Form 20-F for the full year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the “SEC”).

The annual report can be accessed on the Company’s investor relations website at http://ir.zepp.com and on the SEC’s website at www.sec.gov. The Company will provide hardcopies of the annual report, free of charge, to its shareholders and ADS holders upon request. Requests should be submitted to ir@zepp.com.

About Zepp Health Corporation (NYSE: ZEPP)

Zepp Health Corporation (NYSE: ZEPP) is a global smart wearable and health technology leader, empowering users to live their healthiest lives by optimizing their health, fitness, and wellness journeys through its leading consumer brands, Amazfit, Zepp Clarity and Zepp Aura. Powered by its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors and data algorithms, Zepp delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. To date, Zepp has shipped over 200 million units, and its products are available in more than 90 countries and regions. Founded in 2013 as Huami Corp., the Company changed its name to Zepp Health Corporation in February 2021 to emphasize its health focus with a name that resonates across languages and cultures globally. Zepp has team members and offices across globe, especially in Europe and USA regions.

For investor and media inquiries, please contact:

In China:
Zepp Health Corporation
Grace Yujia Zhang
Email: ir@zepp.com 

Piacente Financial Communications
Tel: +86-10-6508-0677
Email: zepp@tpg-ir.com 

 

Amcor to report fiscal 2025 third quarter results

ZURICH, April 26, 2025 /PRNewswire/ — Amcor plc (“Amcor”) (NYSE: AMCR, ASX: AMC) will announce its fiscal 2025 third quarter results for the three month period ended March 31, 2025, after the U.S. market closes on Wed., April 30, 2025. 

Amcor will announce its fiscal 2025 third quarter results on Wed., April 30, 2025.
Amcor will announce its fiscal 2025 third quarter results on Wed., April 30, 2025.

A conference call and webcast to discuss Amcor’s results will be held at 5.30 p.m. U.S. Eastern Daylight Time on Wed., April 30 / 7.30 a.m. Australian Eastern Standard Time on Thurs., May 1. For those wishing to participate in the call, please use the following dial-in numbers:

USA:                            800 715 9871 (toll-free)
                                    646 307 1963 (local)

Australia:                     1800 519 630 (toll-free)
                                    02 9133 7103 (local)

United Kingdom:          0800 358 0970 (toll-free)
                                     020 3433 3846 (local)

Hong Kong:                 +852 3002 3410 (local)

Singapore:                   +65 3159 5133 (local)

All other countries:      +1 646 307 1963 (this is not a toll-free number)

Conference ID             2990465

Access to the webcast and supporting materials will be available via the Investors section of Amcor’s website (www.amcor.com/investors). A webcast replay will be available at the conclusion of the call.

Those wishing to pre-register and access the webcast can do so following this link:   https://events.q4inc.com/attendee/903988368

About Amcor

Amcor plc is a global leader in developing and producing responsible packaging solutions across a variety of materials for food, beverage, pharmaceutical, medical, home and personal-care, and other products. Amcor works with leading companies around the world to protect products, differentiate brands, and improve supply chains. The Company offers a range of innovative, differentiating flexible and rigid packaging, specialty cartons, closures and services. The company is focused on making packaging that is increasingly recyclable, reusable, lighter weight and made using an increasing amount of recycled content. In fiscal year 2024, 41,000 Amcor people generated $13.6 billion in annual sales from operations that span 212 locations in 40 countries. NYSE: AMCR; ASX: AMC www.amcor.com  I  LinkedIn I  YouTube

 

Webull Files Annual Report on Form 20-F for Year Ended December 31, 2024

ST. PETERSBURG, Fla., April 26, 2025 /PRNewswire/ — Webull Corporation (NASDAQ: BULL) today announced the filing of its annual report on Form 20-F for the fiscal year that ended on December 31, 2024, with the U.S. Securities and Exchange Commission (the “SEC”). The annual report on Form 20-F can be accessed on the Investor Relations section of Webull’s website at https://www.webullcorp.com/investor-relations/sec or on the SEC’s website at www.sec.gov.

Shareholders and holders of Webull’s securities may request a hard copy of the Webull’s annual report on Form 20-F containing the audited consolidated financial statements, free of charge, by contacting Webull at 200 Carillon Parkway, St. Petersburg, Florida 33716.

For enquiries, please contact:
ir@webullcorp.com

About Webull
Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 23 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures and fractional shares through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at https://www.webullcorp.com/

MDJM LTD Announces Receipt of Nasdaq Delisting Determination and Plan to Request a Hearing before the Nasdaq Hearings Panel

LETHAM, Scotland, April 26, 2025 /PRNewswire/ — MDJM LTD (Nasdaq: UOKA) (the “Company” or “MDJM”), an integrated global culture-driven asset management company, today announced that the Company received a staff determination letter (the “Letter”), on April 23, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, due to the Company’s failure to regain compliance with a minimum bid price of $1.00 per share requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), Nasdaq has determined (the “Determination”) that Company’s securities will be scheduled for delisting from Nasdaq unless the Company requests an appeal of the Determination to a Hearings Panel (the “Panel”).

On October 23, 2024, the Company received a letter from Nasdaq (the “Notice”), notifying the Company that based upon the closing bid price of its securities for the last 30 consecutive business days preceding the Notice, the Company was not in compliance with the Minimum Bid Requirement.

In accordance with Listing Rule 5810(c)(3)(A), the Notice provided the Company a period of 180 calendar days from the date of the Notice, or until April 21, 2025, to regain compliance with the Minimum Bid Requirement. According to the Letter, the Company had not regained compliance with the Minimum Bid Requirement as of April 21, 2025, and is not eligible for a second 180-day period. Specifically, the Company does not comply with the initial listing requirement of $5,000,000 minimum stockholders’ equity for The Nasdaq Capital Market, as contemplated for a second 180-day period.

Unless the Company requests an appeal of the Determination by April 30, 2025, the Company’s securities will be suspended at the opening of business on May 2, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq.

The Company plans to appeal the Determination to the Panel in due course. A hearing request will stay the suspension of the Company’s securities and the filing of Form 25-NSE pending the Panel’s decision. The Company is considering all options available to it, including a reverse stock split, and will provide its shareholders with material updates when they are available.

About MDJM LTD

MDJM LTD is a global culture-driven asset management company focused on transforming historical properties into cultural hubs that integrate modern digital technology with rich historical value. The Company has been expanding its operations in the UK, where it is developing projects such as Fernie Castle in Scotland and the Robin Hill Property in England. These properties are being remodeled into multi-functional cultural venues that will feature fine dining, hospitality services, art exhibitions, and cultural exchange events. As part of its broader strategy, MDJM seeks to position itself as a hub for artisan exchanges, art shows, and sales, leveraging its historical properties as platforms for promoting Eastern and Western cultural exchanges. This initiative reflects the Company’s commitment to furthering its global market expansion and enhancing its cultural business footprint. For more information regarding the Company, please visit https://www.ir-uoka.com/.

Forward-Looking Statements

This announcement contains forward-looking statements. Please refer to the explanations of the usage of such forward-looking statements at https://www.ir-uoka.com/forward-looking-statements.  

BLUETTI Apex 300 and Full Ecosystem In-Person Debut at Media Day: Innovation Meets Sustainability

SHENZHEN, China, April 26, 2025 /PRNewswire/ — Global clean energy leader BLUETTI, unveiled for the first time the complete Intelligent Ecosystem built around its new flagship—the Apex 300, a sustainable and versatile power station. The debut took place during the Media Day of Global Connect Innovation Week hosted by  iMpact Communications, offering global media an exclusive preview of the full accessory lineup that transforms the Apex 300 into a truly all-scenario energy hub.

BLUETTI Apex 300 Versatile Power Station and the Full Intelligent Ecosystem
BLUETTI Apex 300 Versatile Power Station and the Full Intelligent Ecosystem

More than just a product launch, the event fostered real dialogue and meaningful connections with media from around the world—a step forward in BLUETTI’s ongoing mission to make sustainable energy solutions more accessible, versatile, and deeply human-centered.

Innovation—Smarter Ecosystem for Real-World Living

At the event, BLUETTI walked media professionals through real-life use cases powered by its innovative Intelligent Ecosystem—showcasing how the Apex 300 becomes a tailored energy solution across a wide range of scenarios.

  • For modern homes, the Hub A1 Parallel Box allows the Apex 300 to scale up with ease—linking up to three units and supporting up to 18 B300K Expansion Batteries for a full week of dependable emergency power. When combined with the Reliance Sub Panel and AT1 Smart Distribution Box, the system unlocks seamless, fully automated whole-home backup while helping reduce electricity bills through peak shaving and load shifting—making clean energy not just reliable, but cost-effective too.
  • For outdoor adventures and RV living, BLUETTI’s foldable solar panels are easy to carry, quick to deploy, and work seamlessly with the Apex 300 to capture energy on the go. Taking versatility to the next level, the all-new Hub D1 DC Hub delivers 700W of reliable output—including a secure 600W Anderson port—allowing RVers to power multiple devices at once without overload concerns, making it a perfect companion for the solar generator for RVs.
  • For off-grid cabins or homes already equipped with rooftop solar and inverters, the SolarX 4K Solar Charge Controller connects easily with minimal setup required for home battery backup. Even better, it helps the Apex 300 achieve an industry-leading 2-year payback—keeping upfront investment low while delivering maximum long-term value.

Sustainability, Not as a Trend—but as a Foundation

At BLUETTI, sustainability was never a catchphrase—it’s the heart of the brand. From the initial product development to the company’s core values, every step has been grounded in this commitment.

The Apex 300 didn’t emerge from a boardroom brainstorm—it came from listening. Listening to families facing blackouts, to travelers chasing sunrises, and to communities needing power beyond the grid. The vision was simple: create a power solution that goes where people go, adapts when life shifts, and stays with them—year after year.

With just 20W standby power consumption, the Apex 300 Portable Power Station is 40% more efficient than its peers. Inside, it houses a second-generation automotive-grade LFP battery, designed to last up to 17 years. These aren’t just numbers—they’re a sincere promise. A promise that clean energy should be dependable, long-lasting, and always within reach.

About BLUETTI  

BLUETTI is a dedicated advocate for sustainability, integrating ESG principles throughout product design and corporate initiatives. Through impactful projects like LAAF (Light An African Family), BLUETTI provides affordable, sustainable energy solutions to communities across Africa. By partnering with Leave No Trace, a 501(c)(3) nonprofit, BLUETTI supports responsible outdoor recreation through clean energy solutions that minimize environmental footprints. This blend of craftsmanship, reliability, and a focus on real-world needs is what makes BLUETTI trusted in over 110 countries and regions. 

Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab

HONG KONG, April 26, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical Products Administration (NMPA) for its supplementary New Drug Application (sNDA) for use as a monotherapy for the first-line treatment of PD-L1-positive (TPS ≥ 1%) non-small cell lung cancer (NSCLC) in patients who are negative for epidermal growth factor receptor (EGFR) gene mutations and anaplastic lymphoma kinase (ALK) gene mutations. This indication marks Ivonescimab’s second major approval.

The sNDA approval is based on the breakthrough results of the AK112-303/HARMONi-2 Phase III study, which is a randomized, double-blind, controlled study that directly compared ivonescimab with pembrolizumab in first line PD-L1 positive NSCLC.

  • Ivonescimab demonstrated a statistically significant improvement in the trial’s primary end point, median progression-free survival (PFS) when compared to pembrolizumab, with a median PFS of 11.14 months, achieving a hazard ratio (HR) of 0.51 reducing the risk of disease progression or death by 49%.
  • An interim analysis of OS conducted at 39% data maturity (α=0.0001), indicated a clinically meaningful improvement in OS with ivonescimab compared to pembrolizumab, with a hazard ratio (HR) of 0.777, reflecting a 22.3% reduction in the risk of death.
  • Ivonescimab is the first therapy to achieve statistically significant positive results in a Phase III trial compared with pembrolizumab in a head-to-head setting.
  • Ivonescimab represents a new, more effective, and safer “chemotherapy-free” option for the first-line treatment of NSCLC.

Ivonescimab is the first bispecific antibody approved globally with a dual “cancer immunotherapy + anti-angiogenesis” mechanism. It has already shown significant positive results in three Phase III trials for lung cancer, including 1) treatment for EGFR-TKI-resistant NSCLC, 2) comparison with pembrolizumab in PD-L1-positive NSCLC, and 3) treatment in combination with chemotherapy versus tislelizumab in combination with chemotherapy in squamous NSCLC.

Professor Zhou Caicun, principal investigator of the HARMONi-2 trial, director of the Department of Oncology at the Shanghai East Hospital, Tongji University, commented:

“The Phase III HARMONi-2 study demonstrated that ivonescimab offers significant improvements in progression-free survival (PFS) and overall survival (OS) compared to pembrolizumab. This breakthrough provides a safer and more effective first-line treatment option for NSCLC, particularly beneficial for patients who need better efficacy or quality of life, or those who are not suitable for chemotherapy due to its side effects.

Ivonescimab has also gained widespread recognition in treating EGFR-TKI-resistant NSCLC. The recent Phase III trial combining ivonescimab with chemotherapy, compared to tislelizumab for squamous NSCLC, showed promising positive results. Ivonescimab is now positioned as a new standard of care for both first- and second-line treatment in lung cancer. We are optimistic about its continued success in global Phase III trials and its potential to redefine cancer treatment standards worldwide.”

Dr. Xia Yu, Founder, Chairwoman, President, and CEO of Akeso, commented:

“We are thrilled to announce the approval of ivonescimab as a first-line treatment for PD-L1-positive NSCLC, a major breakthrough in cancer immunotherapy. This milestone is a result of the dedication of investigators, participants, and patients, and we sincerely thank all of them. We also appreciate the regulatory authorities for their efficient and diligent review, which enables us to offer this new treatment to patients in China.

Ivonescimab has shown superior efficacy over pembrolizumab in the HARMONi-2 Phase III trial, becoming the first therapy to achieve this globally. Positive results so far from three pivotal Phase III lung cancer trials further establish ivonescimab as a next-gen IO treatment with strong global potential.

The clinical data highlights ivonescimab’s exceptional efficacy and safety benefits for patients across various cancer types. Beyond lung, ivonescimab has demonstrated promising potential as first-line treatment for other key cancers, including breast, head and neck, biliary tract, and colorectal cancer, supported by, over 12 ongoing Phase III trials. Akeso, along with our partner Summit, are committed to advancing ivonescimab as a cornerstone of global cancer immunotherapy, aiming to provide safer, more effective treatment options for patients worldwide.”

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 4 new drugs with 4 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

 

 

Vivienne Westwood dazzles at Barcelona Bridal Night with an epic show

In the cloister of the historic building of the University of Barcelona

BARCELONA, Spain, April 26, 2025 /PRNewswire/ — The British brand Vivienne Westwood was the star of the Barcelona Bridal Night, held last night as part of the Barcelona Bridal Fashion Week (BBFW). Presenting its 2026 Bridal Collection, the iconic fashion house captivated the more than 450 attendees, offering an unforgettable experience of elegance, rebellion, and romance in what was the first show focused solely on its bridal fashion line.

Simonetta Gianfelici at Vivienne Westoood Barcelona’s Catwalk
Simonetta Gianfelici at Vivienne Westoood Barcelona’s Catwalk

The 19th-century historic building of the University of Barcelona was the chosen venue for this special event. Models paraded in 34 made to order and haute couture bridal gowns, walking through the cloister surrounding the central garden, where the blooming orange trees provided a natural backdrop to the show.

Vivienne Westwood’s creative director, Andreas Kronthaler said: “Bridal has always been an important part of the house, since I started working with Vivienne in the early 90s. We are delighted to be showing our first bridal show here in this fantastic city; we took the grandeur of the boulevards and architecture as our first point of inspiration.”

He continued: “The collection is a pot pourri of past, present and future. Corsetry is the foundation; it enhances you and gives you presence. And tailoring – to add a masculine flair.”

We looked again to our rose print, inspired by the watercolours of 18th century botanist Pierre-Joseph Redouté. We added orange blossom from the courtyard of the university, a symbol of purity and beauty; subdued and layered with tulle – tender, romantic. Rich jacquard in ‘Absence of roses’ – classical. There is linen and cotton, washed georgette and chiffon, to make things look as if they have been worn time and again. The lightest organza, lots of lace, and pale pink duchesse from Italy. Each character tells a story.”

Andreas concluded: “Simonetta (Gianfelici) wears the Madame de Pompadour gown, inspired by the François Boucher painting (1756), this time in white. Vivienne would have loved it – it was her favourite dress of all time.”

Additionally, from today and until Sunday, the Trade Show will open its doors in Halls 1 and 2 and the Plaza de l’Univers at the Montjuïc venue, with nearly 450 brands offering buyers from around the world a wide range of bridal, groom, party, ceremony, red carpet, and accessory dresses.

Photo – https://laotiantimes.com/wp-content/uploads/2025/04/vivienne_westoood_barcelona.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/04/fira_barcelona_logo-1.jpg

Baidu Launches ERNIE 4.5 Turbo, ERNIE X1 Turbo and New Suite of AI Tools to Empower Developers and Supercharge AI Innovation

  • Following the release of two models in mid-March, Baidu unveiled ERNIE 4.5 Turbo and ERNIE X1 Turbo today, which stand out for their multimodal capabilities, strong reasoning, and low costs. ERNIE 4.5 Turbo delivers faster responses while priced at 20% of ERNIE 4.5; ERNIE X1 Turbo, featuring enhanced capabilities, is half the price of ERNIE X1.
  • In addition to the models, Baidu also unveiled an array of AI applications, including Xinxiang, a multi-agent collaboration app, enabling full task delivery from a single sentence prompt, as well as highly convincing digital humans.
  • Baidu also announced an AI Open Initiative as well as the integration of MCP into some existing products to enable effortless experience for the developers to access and utilize Baidu’s suite of services.

WUHAN, China, April 26, 2025 /PRNewswire/ — Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888), a leading AI company with a strong internet foundation, today introduced a new suite of AI innovations at its annual developer conference Baidu Create 2025. At the event, Baidu co-founder and CEO Robin Li introduced ERNIE 4.5 Turbo and ERNIE X1 Turbo, the latest two models of the company, along with a series of AI applications and advancements, and committed to empowering developers to fully embrace MCP (Model Context Protocol).

“Our releases aim to empower developers to build the best applications — without having to worry about model capability, costs, or development tools,” Li said in his keynote, addressing an audience of over 5,000 developers and tech enthusiasts. “Without practical applications, neither advanced chips nor sophisticated models hold value. While there will be a multitude of models, it is the applications that will truly dominate in the future. Applications are where true power lies,” Li added.

ERNIE 4.5 Turbo and ERNIE X1 Turbo: Faster and Cheaper

Baidu introduced ERNIE 4.5 Turbo and ERNIE X1 Turbo at Create 2025, both of which feature enhanced multimodal capabilities, strong reasoning, low costs, and are available for users to access on ERNIE Bot now free of charge. The two models were launched to address common pain points in the industry, including single-modality, high-hallucination, slow-response and high-price, Li noted.

ERNIE X1 Turbo is an upgraded deep thinking reasoning model. Featuring a more advanced chain of thought, stronger deep thinking capabilities, and further enhanced multimodal and tool invocation abilities, it excels in Q&A, literary creation, and logical reasoning, outperforming DeepSeek R1 as well as the latest version of V3.

ERNIE X1 Turbo offers improved performance while being priced at half of ERNIE X1, making it only 25% of the price of DeepSeek R1. The input price is RMB 1 per million tokens, and the output price is RMB 4 per million tokens.


ERNIE 4.5 Turbo demonstrates overall progress in hallucination reduction, logical reasoning, and coding abilities, with faster response. The multimodal capabilities of ERNIE 4.5 Turbo are on par with GPT-4.1 and superior to GPT-4o across multiple benchmarks. For ERNIE 4.5 Turbo, the input price is only RMB 0.8 per million tokens, and the output price is RMB 3.2 per million tokens, 80% off the price of ERNIE 4.5, 0.2% of GPT-4.5 and 40% of DeepSeek V3.


Both ERNIE 4.5 Turbo and X1 Turbo have further enhanced their multimodal capabilities. “Multimodality will become a standard feature of future foundation models. The market for pure text-based models will shrink, while the market for multimodal models will continue to grow,” Li predicted in his keynote.

The two models follow the launch of ERNIE 4.5, the company’s first native multimodal foundation model, and ERNIE X1, a multimodal deep-thinking reasoning model capable of tool use, both of which received strong market recognition after their debut on March 16, 2025.

AI Application Frontrunners: Highly Convincing Digital Humans and Multi-agent Tool Xinxiang

The highly convincing digital human is one of the key applications that exemplify the capabilities of multimodality. “AI digital humans are one of the most exciting breakthrough applications in 2025,” Li said in his speech.

Li introduced Baidu’s highly convincing AI digital human, which features ultra-realistic voice and appearance, as well as more professional content-generation and more flexible interactions. Baidu’s Huiboxing, a digital human livestream platform powered by AI, now offers a feature to create a digital human in one click where users can upload a video as short as two minutes before the system can generate a personalized digital human ready to go live.

Over the past year, agents have transitioned from a niche concept to a core field of AI applications. Notably, coding agents have rapidly gained traction, with Baidu offering tools like Comate for code assistance and Miaoda, a no-code platform for multi-agent collaboration. In March, Miaoda was made available to the public, allowing users to generate applications with a single sentence.

“There are nearly 30 million programmers and 8 billion people globally. As technologies become more accessible, everyone can possess the capabilities of a programmer,” said Li.

At the event, Baidu also officially released the multi-agent collaboration app Xinxiang, a “general super agent” capable of solving complex problems for users in a one-stop manner. Currently, Xinxiang covers 200 task types in scenarios such as knowledge-analysis, travel-planning, studying, and office work. In the future, Baidu plans to expand the number of task types to over 100,000.

Li also introduced Cangzhou OS, the first content operating system jointly launched by Baidu Wenku and Baidu Drive. Powered by Cangzhou OS, Baidu Drive has launched AI Note, the industry’s first multimodal AI note-taking tool. Users can generate quick notes, mind maps, and quizzes from watching educational videos with just a single click.

To date, Baidu Wenku’s AI features have amassed 40 million paying users and 97 million monthly active users (MAUs), while Baidu Drive’s AI features serve more than 80 million MAUs.

Building a Thriving Ecosystem: AI Open Initiative, MCP and ERNIE Cup

Addressing the booming AI application market, Baidu introduced a series of initiatives aimed at supporting AI developers in adapting to the emerging trend.

Baidu Search Open Platform has launched the AI Open Initiative (sai.baidu.com), providing developers of AI agents, H5 pages, mini programs, and standalone apps with traffic and monetization opportunities, as well as access to the latest AI services through a diversified content and service distribution system.

Also at the event, Baidu announced full support to enable developers to adopt Model Context Protocol (MCP). Li compared MCP to installing a “universal socket” for AI — enabling seamless connections between external services and large models through standardized interfaces. Live demos showcased the integration of MCP across a series of Baidu proprietary services, including the Baidu Qianfan Foundation Model Platform, Baidu Search, e-commerce, and Baidu Drive.

To further support innovation in AI, Baidu announced the third ERNIE Cup Innovation Challenge at Create 2025. This year’s challenge will double the prize amounts from previous years, offering up to RMB 70 million in investment for outstanding projects.

At the same time, Baidu announced that over the next five years, the company will scale up its efforts to cultivate an additional 10 million AI talents for society.

Baidu Create is Baidu’s annual tech event for the developer community, serving as a platform for technology launches and knowledge exchange. This year’s conference centered around the theme of “Models Lead, APPs Rule” and featured six sub-forums on subjects such as MCP, agents, DeepSeek and more.

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong internet foundation, trading on the NASDAQ under “BIDU” and HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.

Media Contact
intlcomm@baidu.com